Selective androgen receptor modulators, commonly called SARMs, are experimental drugs that were designed to stimulate muscle and bone growth while minimizing the unwanted side effects of traditional anabolic steroids. None have been approved for medical use by any major regulatory agency, yet they are widely sold online and used by men seeking to build muscle, cut fat, or improve athletic performance. The gap between what SARMs promise and what the evidence actually shows is significant, and the health risks that have emerged in recent years are serious enough that anyone considering these compounds should understand both sides of the story.
How SARMs Are Supposed to Work
Traditional testosterone and anabolic steroids flood the entire body with androgenic activity. That builds muscle, but it also enlarges the prostate, causes acne, accelerates hair loss, and can convert into estrogen through aromatization. SARMs were developed as a workaround. They bind to the same androgen receptor that testosterone does, but their chemical structure causes the receptor to fold into a slightly different shape depending on the tissue. In theory, this means a SARM can act as a strong activator in muscle and bone while behaving as a weak activator or even a blocker in the prostate and skin.
The nonsteroidal SARMs that dominate the gray market today do not serve as substrates for aromatase or 5-alpha reductase, the two enzymes responsible for converting testosterone into estrogen and dihydrotestosterone respectively.1PubMed Central. Selective androgen receptor modulators as function promoting therapies That means they should not cause breast tissue growth or the aggressive androgenic effects seen with steroids. In preclinical studies, many SARMs delivered on this premise, building muscle in rodents without proportionally enlarging the prostate. A safety comparison review noted that SARMs are highly specific for androgen receptors, orally available, and act as strong agonists in skeletal muscle and bone while behaving as weak agonists or antagonists in tissues like the prostate and sebaceous glands.2PubMed. Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids
That is the theory. The reality in humans is less tidy, and the “selective” part of the name oversells how cleanly these drugs separate desirable from undesirable effects once they enter a living person’s body.
What Human Trials Have Actually Shown
Enobosarm (also sold under the name ostarine or MK-2866) is the most clinically studied SARM. In a placebo-controlled phase II trial involving healthy elderly men and postmenopausal women, the 3 mg dose produced statistically significant increases in total lean body mass, along with improvements in physical function and insulin resistance.3PubMed Central. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial A separate trial in cancer patients with cachexia, the severe muscle wasting that accompanies advanced disease, also showed significant gains in lean mass.4PubMed Central. Selective androgen receptor modulators as function promoting therapies
Those results sound impressive, and they are real. But some context matters. The lean mass gains in the phase II trial were dose-dependent and modest compared with what anabolic steroids produce. The trial populations were elderly people and cancer patients losing muscle, not young healthy men trying to get bigger. Researchers have been interested in SARMs primarily as treatments for sarcopenia, frailty, and disease-related wasting, not as performance enhancers. And even within that clinical context, no SARM has cleared the bar for regulatory approval. Enobosarm’s phase III trials for cancer cachexia failed to meet their primary endpoint of improved physical function in both trials, despite showing lean mass gains. That failure is why you still cannot get a prescription for any SARM anywhere in the world.
The broader clinical picture for SARMs as potential treatments for male hypogonadism has been explored in reviews noting that SARMs may represent a promising alternative to testosterone therapy because they are orally active, non-aromatizable, and tissue-selective, with animal studies showing positive effects on libido and muscle mass.5PubMed Central. Selective androgen receptor modulators: the future of androgen therapy? But “promising in animal models” is a long way from proven in humans, and the gap between those two stages is where most drugs fail.
The Liver Problem
The most alarming risk that has surfaced in published case reports is liver injury, and the pattern is consistent enough to take seriously. A review of adverse event reports found that since 2020, at least 20 published cases of adverse events linked to SARM use have appeared in the medical literature, most of them involving drug-induced liver injury.6European Journal of Clinical Pharmacology. Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases The dominant pattern is cholestatic liver injury, where bile flow becomes obstructed, leading to jaundice, intense fatigue, and elevated bilirubin.
Two well-documented cases involved young men who used ligandrol or ostarine for several weeks and developed acute liver injury after stopping the SARMs and beginning post-cycle therapy. Liver biopsies in both cases showed cholestatic injury with bile plugs and ductopenia, though without significant fibrosis. Recovery was prolonged.7PubMed Central. Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review In another published case, RAD-140 (testolone) was linked to severe cholestatic liver injury with the potential to progress to acute liver failure.8Australian Prescriber. Severe liver injury following use of RAD-140, a selective androgen receptor modulator, for body building
One especially striking case involved a 27-year-old man who had used three different SARMs and presented with progressive weakness. His creatinine was 4.8 mg/dL and his total bilirubin was 43.3 mg/dL, indicating both kidney and liver damage. Biopsies confirmed bile cast nephropathy caused by SARM-associated liver injury, meaning the liver damage was severe enough that it spilled over and harmed his kidneys.9PubMed Central. Bile Cast Nephropathy Because of Acute Liver Injury Associated With Selective Androgen Receptor Modulators
These are case reports, not controlled studies, so they cannot tell us exactly how common liver injury is among SARM users. But the consistency of the pattern across different SARMs (ostarine, ligandrol, RAD-140), different countries, and different user profiles strongly suggests the risk is real and not limited to a single compound. The fact that many users also take post-cycle therapy drugs alongside or after SARMs complicates the picture, because those substances may contribute to or worsen the liver damage.
Hormonal Suppression and Fertility
One of the most widely underestimated risks among men using SARMs is suppression of the body’s own testosterone production. SARMs activate androgen receptors, and the brain’s hypothalamus and pituitary gland respond to that signal by reducing their output of luteinizing hormone and follicle-stimulating hormone, the hormones that tell the testes to produce testosterone and sperm. A case report of an otherwise asymptomatic SARM user revealed suppression of the pituitary-gonadal axis alongside elevated liver enzymes.10Bulletin of the National Research Centre. Metabolic and hormonal dysfunction in asymptomatic patient using selective androgen receptor modulators: a case report
This suppression is not a minor side effect. When your natural testosterone drops while you are taking SARMs, you may not notice because the SARM is partially filling the role. But when you stop, there is a gap. Your natural production has been dialed down and takes time to recover, leaving you in a state functionally similar to hypogonadism: low energy, poor mood, reduced libido, and muscle loss. This is the same rebound problem that drives steroid users to post-cycle therapy, and it is now driving SARM users to do the same.
Animal research has gone further, showing that some SARMs can markedly suppress sperm production. In rat studies, one SARM caused marked suppression of spermatogenesis after ten weeks of treatment.11The Journal of Pharmacology and Experimental Therapeutics. A Selective Androgen Receptor Modulator for Hormonal Male Contraception This was actually being explored as a feature, not a bug: researchers have investigated SARMs as potential male contraceptives, since they could suppress sperm production while maintaining androgenic support in other tissues.12PubMed Central. Hormonal approaches to male contraception For men who are not trying to become contraceptive test subjects, that same property is a serious concern. If you are planning to have children, using SARMs could temporarily or potentially longer-term impair your fertility.
Recovery from androgen-induced fertility suppression typically involves a combination of medications including selective estrogen receptor modulators (SERMs like clomiphene), hCG, aromatase inhibitors, and sometimes recombinant FSH.13PubMed. Anabolic steroid misuse and male infertility: management and strategies to improve patient awareness That recovery protocol exists, but it takes time, medical supervision, and does not always work quickly or completely.
Cardiovascular Effects
Beyond the liver and hormonal system, SARMs have shown unfavorable effects on blood lipids that raise concerns about long-term cardiovascular health. In a controlled study examining HDL cholesterol, SARM treatment significantly suppressed both HDL cholesterol and apolipoprotein A-I, while also increasing hepatic lipase activity.14PubMed Central. Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles HDL is protective against cardiovascular disease, so driving it down is moving the needle in the wrong direction.
Reviews of androgen abuse more broadly have associated it with increased mortality and multisystem adverse effects, including cardiovascular toxicity, infertility, hypogonadism, liver damage, and mental health disorders.15Annals of the New York Academy of Sciences. Androgen abuse: Risks and adverse effects in men SARMs are typically lumped into this broader category of androgen misuse, and while they may carry lower cardiovascular risk than full-dose injectable steroids, “lower than steroids” is a low bar. The HDL suppression seen in clinical data is a physiological effect, not a contamination issue, meaning it appears even when the SARM is pharmaceutical-grade.
What Is Actually in the Bottle
Product quality may be the single most underappreciated hazard of SARM use. A landmark analysis published in JAMA tested 44 products sold online as SARMs. Only about half actually contained any SARM at all. Roughly 39% contained a completely different unapproved drug, including compounds like ibutamoren (a growth hormone secretagogue) and GW501516 (a PPAR-delta agonist that was abandoned in preclinical development after it caused cancer in rodents at certain doses). In about 9% of products, no active compound was detected at all. And in only 41% did the amount of active compound match what the label stated.16JAMA. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet
An Australian analysis of 111 SARM products painted a similarly bleak picture. While most products at least correctly identified the main active ingredient on the label, 90 out of 111 were contaminated with other performance-enhancing substances. Only about a third of the products were considered of good quality when assessed for both dosage accuracy and consistency.17Performance Enhancement & Health. “For research use only”: A comprehensive analysis of SARMs and related IPEDs purchased on local Australian websites between 2017 and 2018
This means that when a man buys a bottle labeled “ostarine 25 mg,” there is roughly a coin-flip chance that what he gets matches that description. He could be taking a different SARM, a different drug entirely, a lower or higher dose than expected, or essentially nothing. Some of the substances found as contaminants carry their own serious risks. GW501516, for example, has never been approved for any use because of safety signals in animal testing. The “research chemical” disclaimer that appears on many of these product pages is a legal fiction that shields the seller but does nothing to protect the buyer.
Bone Health Research
One of the more genuinely interesting areas of SARM research is bone density, though the findings are exclusively from animal models. In rat models of osteoporosis, several different SARMs have increased bone mineral density. The compound S-40503, for instance, increased femoral bone mineral density and biomechanical strength of cortical bone in both male and female rats with surgically induced hormone deficiency, while an estrogen-based treatment only prevented bone loss rather than building new bone.18Biological and Pharmaceutical Bulletin. Bone Anabolic Effects of S-40503, a Novel Nonsteroidal Selective Androgen Receptor Modulator (SARM), in Rat Models of Osteoporosis
Ostarine has also been tested in rat osteoporosis models. When given preventively to castrated rats, it preserved cortical and trabecular bone density compared with untreated castrated animals. However, the therapeutic application (giving ostarine after bone loss had already occurred) was less impressive, increasing only cortical femoral density without affecting other bone parameters.19PubMed Central. Treatment of osteoporosis using a selective androgen receptor modulator ostarine in an orchiectomized rat model In a bone fracture healing model, preventive enobosarm treatment increased callus area and density but also increased prostate weight, while therapeutic use actually impaired healing by reducing callus density and delaying bone bridging.20Calcified Tissue International. Effect of Selective Androgen Receptor Modulator Enobosarm on Bone Healing in a Rat Model for Aged Male Osteoporosis
The bone data underscores a recurring theme with SARMs: the selectivity is partial, not absolute. Even in rat studies, prostate weight increases showed up alongside the bone benefits, and the timing of administration dramatically changed whether the effects were helpful or harmful. Translating these animal results to human medicine remains an open question, and no SARM has been tested in a large human bone density trial.
Legal Status and Anti-Doping
SARMs exist in a regulatory gray zone in most countries. In the United States, they are not approved by the FDA for any medical use. They cannot legally be sold as dietary supplements, though they frequently appear online marketed with “not for human consumption” or “research chemical” disclaimers. The SARMs Control Act, signed into law in 2022, classified SARMs as Schedule III controlled substances in the same category as anabolic steroids, making their sale for non-research purposes a federal offense. Enforcement, however, has been inconsistent, and products remain readily available.
In competitive sports, SARMs have been prohibited by the World Anti-Doping Agency since 2008, and athletes have been caught using them. Anti-doping laboratories can detect SARMs and their metabolites with high sensitivity using mass spectrometry methods.21Forensic Science International. SARM-S4 and metabolites detection in sports drug testing: A case report The detection window varies by compound, but many SARMs can be identified in urine weeks after last use. Athletes have been suspended based on SARM-positive tests even when they claimed ignorance, which ties back to the contamination issue: if a supplement you buy contains an undisclosed SARM, you can still fail a drug test.
The Psychology of “Safer Than Steroids”
Much of the appeal of SARMs rests on the perception that they are a gentler version of anabolic steroids. The marketing language leans heavily on “selective” and “targeted,” implying that you get the muscle-building upside without the downsides. Androgen use for appearance and performance enhancement is widespread: the lifetime prevalence among men is estimated at around 6.4%, and while steroids dominate that figure, SARMs have carved out a growing share as they are perceived as a low-risk entry point.22Clinical Endocrinology. Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs
That perception is understandable but misleading. SARMs do appear to cause fewer androgenic side effects like acne and hair loss compared with full anabolic steroids, and they do not aromatize to estrogen. But the hormonal suppression, the liver toxicity, and the HDL suppression are not hypothetical risks gleaned from animal studies alone: they are showing up in real human users, documented in peer-reviewed case reports and controlled studies. The fact that SARMs are milder than injectable trenbolone does not make them safe, any more than driving at 80 miles per hour is safe because it is slower than 120.
The dependence patterns around image and performance-enhancing drugs add another layer of concern. Withdrawing from these substances is complicated by both physical symptoms (the testosterone crash, fatigue, muscle loss) and psychological ones (body image anxiety, fear of losing gains). These withdrawal challenges are recognized as a clinical problem requiring specific management approaches, not something a user can necessarily gut through on their own.
Talking to Your Doctor About SARM Use
If you have used SARMs and are experiencing symptoms like yellowing of the skin or eyes, unusual fatigue, dark urine, or abdominal pain, you should get liver function tests promptly. If you are experiencing low libido, depressed mood, or fatigue after stopping SARMs, hormonal bloodwork including testosterone, LH, and FSH can help clarify whether your pituitary-gonadal axis is suppressed. Be honest with your doctor about what you took, how much, and for how long. Many physicians are now familiar with SARM-related presentations, and withholding information only delays accurate diagnosis.
If you are considering SARMs for the first time, the honest assessment is this: they do build some lean mass, but the gains in clinical trials were modest, the products you can actually buy are unreliable, and the risks to your liver, hormones, cardiovascular system, and fertility are real and documented. No SARM has been approved for any use in any country after decades of research, and that is not because regulators are slow. It is because the risk-benefit balance has not cleared the bar that every approved drug must clear.